Month: March 2021

[Updated: 3/31/2021] Can FATE Stock Rebound? The stock price of Fate Therapeutics (NASDAQ: FATE), a biopharmaceuticals company focused on oncology and immunology treatments based on natural killer T-Cell programs, has seen a large 20% drop in just five trading sessions. The decline is driven in part by the broader sell-off in high growth stocks. Separately,
0 Comments
Robert Daly | Getty Images The Biden administration is expanding an existing pause on student loan interest and collections to include more than 1.1 million borrowers who are in default, the U.S. Department of Education announced Tuesday. The borrowers, whose defaulted loans are part of the Federal Family Education Loan program, were ineligible for the
0 Comments
A new COVID-19 stimulus payment is on its way. According to the IRS, more than 90 million Americans have already received theirs with additional checks en route to the remainder of eligible recipients. President Biden signed the American Rescue Plan Act into law March 11th, provisioning a third round of stimulus money which includes $1400
0 Comments
In this article LULU Pedestrians wearing protective masks walk past a Lululemon store in San Francisco, California, on Monday, March 29, 2021. David Paul Morris | Bloomberg | Getty Images Lululemon on Tuesday reported revenue and profit for the holiday quarter that topped analysts’ estimates, boosted by the athletic apparel maker’s online business, and double-digit
0 Comments
In this article VIACP DISCA 9888-HK 700-HK 8604.T-JP CSG.N-CH The warning by Japanese investment bank Nomura that it could incur billions of dollars in losses at a U.S. subsidiary was “pretty unfortunate,” an analyst said on Tuesday. Nomura on Monday flagged a potential $2 billion loss resulting from transactions with a client stateside. The bank’s
0 Comments
Steven Heap/EyeEm/Getty Images The deadline to contribute to individual retirement accounts and health savings accounts is May 17, the same day that individual federal income tax returns are due, the IRS said Monday. The announcement comes after the agency postponed the filing deadline to May 17 from April 15 following increased calls for more time
0 Comments
My IPO research aims to provide investors with more reliable fundamental research to evaluate upcoming IPOs. At the midpoint ($9.7 billion) of its expected IPO price range, Compass’ (COMP) valuation implies it will disrupt the real estate business and generate 2x the revenue of the current largest U.S. brokerage, Realogy. Currently, the company looks more like a traditional brokerage
0 Comments
In this article WPF^ BFT^ NDAQ FNF BX London-based online payments company Paysafe is set to begin trading on U.S. public markets after merging with blank-check company Foley Trasimene Acquisition II Corp, billionaire business and sports executive Bill Foley told CNBC Monday. Foley, who set up the special purpose acquisition company, or SPAC, announced in December
0 Comments
Exhaustive reviews, impossible public interest standards and no guarantee of eventual success: That’s the consensus outlook for mergers and acquisitions activity under the Biden Administration. Nonetheless, M&A is alive and well among the 190 essential services companies I track in the Conrad’s Utility Investor coverage universe. Seven have accepted takeover offers and regulatory approvals are
0 Comments
A Social Security Administration office in San Francisco. Getty Images When the Covid-19 pandemic set in last year, one of the unintentional effects from the deep economic downturn included a potential reduction in Social Security benefits for one group of people. And now, as the U.S. economy is beginning to repair itself, signs point to
0 Comments
Thanks to two stock market pullbacks in 2020 and this current pause to begin 2021, equity prices are likely still “catching up” with their pre-2020 trajectories. Big tech is frothy but many lesser-known dividend growers are still cheap. And that’s music to my ears, because the surest, safest way for us to double our money
0 Comments
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, testifies during a Senate Health, Education, Labor and Pensions Committee hearing on the federal coronavirus response on Capitol Hill on March 18, 2021 in Washington, DC. Susan Walsh | Pool | Getty Images The latest rise in new Covid-19 infections can’t be
0 Comments